{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:49:12Z","timestamp":1791816552438,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ejca.2016.02.025","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:40:53Z","timestamp":1460594453000},"page":"190-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":560,"special_numbering":"C","title":["Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-9823","authenticated-orcid":false,"given":"Lars","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Schmidgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen S.","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"G\u00f6ppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Tietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2822-2057","authenticated-orcid":false,"given":"Ioannis","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-2106","authenticated-orcid":false,"given":"Carsten","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leverkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kirchberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Krackhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie M.","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2016.02.025_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol [Internet]"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.025_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med [Internet]"},{"issue":"8","key":"10.1016\/j.ejca.2016.02.025_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med [Internet]"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.025_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med [Internet]"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.025_bib5","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.025_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol [Internet]"},{"issue":"8","key":"10.1016\/j.ejca.2016.02.025_bib7","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol [Internet]"},{"issue":"21","key":"10.1016\/j.ejca.2016.02.025_bib8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.025_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med [Internet]"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.025_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med [Internet]"},{"issue":"6","key":"10.1016\/j.ejca.2016.02.025_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0000000000000191","article-title":"Acute skin reaction suggestive of pembrolizumab-induced radiosensitization","volume":"25","author":"Sibaud","year":"2015","journal-title":"Melanoma Res [Internet]"},{"issue":"11","key":"10.1016\/j.ejca.2016.02.025_bib12","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.025_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"issue":"18","key":"10.1016\/j.ejca.2016.02.025_bib15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol [Internet]"},{"issue":"10","key":"10.1016\/j.ejca.2016.02.025_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","author":"Kato","year":"2015","journal-title":"J Eur Acad Dermatol Venereol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib18","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","author":"Matsumura","year":"2015","journal-title":"Acta Derm Venereol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib19","article-title":"Pembrolizumab: a new drug that can induce exacerbations of psoriasis","author":"Sahuquillo-Torralba","year":"2015","journal-title":"Actas Dermosifiliogr [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib20","unstructured":"Opdivo: highlights of prescribing information, http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf [accessed 08.10.15]."},{"key":"10.1016\/j.ejca.2016.02.025_bib21","unstructured":"Keytruda: highlights of prescribing information, http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf [accessed 12.10.15]."},{"issue":"6","key":"10.1016\/j.ejca.2016.02.025_bib22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol [Internet]"},{"issue":"3","key":"10.1016\/j.ejca.2016.02.025_bib23","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO.2013.49.0565","article-title":"Acute radiation skin toxicity associated with BRAF inhibitors","volume":"34","author":"Pulvirenti","year":"2016","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib24","article-title":"Lichen planus pemphigoides bei einem 62-j\u00e4hrigen Patienten mit metastasiertem malignen Melanom und kompletter Remission nach Therapie mit Pembrolizumab","volume":"13","author":"Schmidgen","year":"2015","journal-title":"J Dtsch Dermatol Ges [Internet]"},{"issue":"3","key":"10.1016\/j.ejca.2016.02.025_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib26","article-title":"Generalisierte Blasenbildung unter Pembrolizumab-Therapie","volume":"13","author":"Vigl","year":"2015","journal-title":"J Dtsch Dermatol Ges [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.025_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol [Internet]"},{"issue":"21","key":"10.1016\/j.ejca.2016.02.025_bib28","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.025_bib29","article-title":"Nivolumab in previously untreated melanoma without BRAF\u00a0mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.025_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib31","article-title":"Autoimmuncolitiden unter der Behandlung mit Checkpoint-Inhibitor - Calprotektin als pr\u00e4diktiver Marker intestinaler Nebenwirkungen","volume":"13","author":"Koop","year":"2015","journal-title":"J Dtsch Dermatol Ges [Internet]"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2016.02.025_bib32","first-page":"E78","article-title":"Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis","volume":"44","author":"Hundorfean","year":"2012","journal-title":"Endoscopy [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.025_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.025_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","article-title":"Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma","volume":"23","author":"Bernardo","year":"2013","journal-title":"Melanoma Res [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.025_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med [Internet]"},{"issue":"5","key":"10.1016\/j.ejca.2016.02.025_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0000000000000081","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J Immunother [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib37","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209\u2013040","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib38","unstructured":"Yervoy: summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002213\/WC500109299.pdf [accessed 15.10.15]."},{"issue":"12","key":"10.1016\/j.ejca.2016.02.025_bib39","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the Anti-PD-1 and Anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.025_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab [Internet]"},{"issue":"11","key":"10.1016\/j.ejca.2016.02.025_bib41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Invest [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.025_bib42","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.025_bib43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs [Internet]"},{"issue":"33","key":"10.1016\/j.ejca.2016.02.025_bib44","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","article-title":"Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss","volume":"30","author":"Voskens","year":"2012","journal-title":"J\u00a0Clin Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.025_bib45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J Immunother cancer [Internet]"},{"issue":"10","key":"10.1016\/j.ejca.2016.02.025_bib47","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u2013a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.025_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol [Internet]"},{"key":"10.1016\/j.ejca.2016.02.025_bib49","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. (in revision)","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.025_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity [Internet]"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T15:32:10Z","timestamp":1600443130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":50,"alternative-id":["S0959804916001519"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.02.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}